Literature DB >> 21050845

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.

David W Porter1, Nigel Irwin, Peter R Flatt, Christian Hölscher, Victor A Gault.   

Abstract

Enzyme-resistant glucose-dependent insulinotropic polypeptide (GIP) agonists offer therapeutic potential for type 2 diabetes treatment. In addition, there is emerging evidence suggesting that GIP plays a direct role in modulating aspects of brain function. This study compared effects of dietary modification and/or twice-daily injection of the stable GIP agonist, (d-Ala(2))GIP, on metabolic control, cognitive function and hippocampal synaptic plasticity in high-fat fed mice. Young Swiss mice were maintained on high-fat diet for 155 days, at which point half of the animals were switched to standard maintenance diet. Mice were subsequently injected with (d-Ala(2))GIP (25 nmol/kg bodyweight; b.i.d.) or saline vehicle for 28 days. Both dietary intervention and (d-Ala(2))GIP treatment were equally effective in restoring non-fasting glycaemic control (P<0.001) and improving (P<0.05 to P<0.001) glucose tolerance in high-fat fed mice. Switching to standard diet alone or in combination with (d-Ala(2))GIP treatment returned body weights of high-fat fed mice to normal levels by day 28. However, body weights of high-fat fed mice treated with (d-Ala(2))GIP were not significantly different from controls. (d-Ala(2))GIP did not affect food intake or plasma insulin levels irrespective of diet. All mice treated with (d-Ala(2))GIP exhibited a marked increase in recognition index (1.4-fold; P<0.05) highlighting improved cognitive function. Furthermore, switching to standard diet and/or (d-Ala(2))GIP treatment rescued deleterious effects of high-fat feeding on long-term potentiation of synaptic neurotransmission. These results demonstrate that prolonged GIP activation is equally effective or superior to dietary intervention, in improving glucose intolerance and aspects of cognitive function and hippocampal synaptic plasticity in high-fat fed mice.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21050845     DOI: 10.1016/j.ejphar.2010.10.059

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  20 in total

1.  Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.

Authors:  Yukiko Fu; Kentaro Kaneko; Hsiao-Yun Lin; Qianxing Mo; Yong Xu; Takayoshi Suganami; Peter Ravn; Makoto Fukuda
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

2.  Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.

Authors:  Mariana Igoillo-Esteve; Ana F Oliveira; Cristina Cosentino; Federica Fantuzzi; Céline Demarez; Sanna Toivonen; Amélie Hu; Satyan Chintawar; Miguel Lopes; Nathalie Pachera; Ying Cai; Baroj Abdulkarim; Myriam Rai; Lorella Marselli; Piero Marchetti; Mohammad Tariq; Jean-Christophe Jonas; Marina Boscolo; Massimo Pandolfo; Décio L Eizirik; Miriam Cnop
Journal:  JCI Insight       Date:  2020-01-30

Review 3.  Hippocampal insulin resistance and cognitive dysfunction.

Authors:  Geert Jan Biessels; Lawrence P Reagan
Journal:  Nat Rev Neurosci       Date:  2015-10-14       Impact factor: 34.870

4.  Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates.

Authors:  Paul B Higgins; Robert E Shade; Irám P Rodríguez-Sánchez; Magdalena Garcia-Forey; M Elizabeth Tejero; V Saroja Voruganti; Shelley A Cole; Anthony G Comuzzie; Franco Folli
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-08-16       Impact factor: 4.310

5.  Stop signs in hippocampal insulin signaling: the role of insulin resistance in structural, functional and behavioral deficits.

Authors:  Jim R Fadel; Lawrence P Reagan
Journal:  Curr Opin Behav Sci       Date:  2015-12-01

6.  Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

Authors:  Therese S Salameh; Elizabeth M Rhea; Konrad Talbot; William A Banks
Journal:  Biochem Pharmacol       Date:  2020-08-02       Impact factor: 5.858

Review 7.  Effects of diabetes on hippocampal neurogenesis: links to cognition and depression.

Authors:  Nancy Ho; Marilyn S Sommers; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2013-05-13       Impact factor: 8.989

Review 8.  New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.

Authors:  Nigel Irwin; Peter R Flatt
Journal:  World J Diabetes       Date:  2015-11-10

Review 9.  Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.

Authors:  Christian Hölscher
Journal:  Br J Pharmacol       Date:  2021-05-29       Impact factor: 8.739

10.  Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model.

Authors:  Emilie Faivre; Christian Hölscher
Journal:  Alzheimers Res Ther       Date:  2013-04-19       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.